Saltar al contenido
Merck

PHR1271

3,4-Dihidroxi-L-fenilalanina

Pharmaceutical Secondary Standard; Certified Reference Material

Sinónimos:

3-(3,4-Dihidroxifenil)-L-alanina, L-3-Hidroxitirosina, L-DOPA, Levodopa

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño

Acerca de este artículo

Fórmula lineal:
(HO)2C6H3CH2CH(NH2)CO2H
Número CAS:
59-92-7
Peso molecular:
197.19
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
329823267
EC Number:
200-445-2
Beilstein/REAXYS Number:
2215169
MDL number:
MFCD00002598

Documentos clave

Ver Toda la documentación
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle

InChI key

WTDRDQBEARUVNC-LURJTMIESA-N

InChI

1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14)/t6-/m0/s1

SMILES string

N[C@@H](Cc1ccc(O)c(O)c1)C(O)=O

grade

certified reference material, pharmaceutical secondary standard

agency

traceable to Ph. Eur. L0400000, traceable to USP 1361009

API family

levodopa

CofA

current certificate can be downloaded

technique(s)

HPLC: suitable, gas chromatography (GC): suitable

mp

276-278 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

Quality Level

300

Gene Information

human ... DRD3(1814)

¿Está buscando productos similares? Visita Guía de comparación de productos

Categorías relacionadas

General description

Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards. Levodopa is a metabolic precursor of the neurotransmitter dopamine and is widely used in the treatment of Parkinson′s disease.

Application

Levodopa may be used as a pharmaceutical reference standard for the quantification of the analyte in pharmaceutical formulations using flow injection spectrophotometric method and 1H nuclear magnetic resonance spectroscopy.
These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements.

Analysis Note

These secondary standards offer multi-traceability to the USP and EP (PhEur) primary standards, where they are available.

Other Notes

This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis.
To see an example of a Certificate of Analysis for this material enter LRAC2957 in the slot below. This is an example certificate only and may not be the lot that you receive.

pictograms

Exclamation mark
GHS07

signalword

Warning

Hazard Classifications

Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

Clase de almacenamiento

11 - Combustible Solids

wgk

WGK 3

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Parkinson's Disease and Related Disorders, 506(1), 97-104 (2006)
1H nuclear magnetic resonance spectroscopy analysis for simultaneous determination of levodopa, carbidopa and methyldopa in human serum and pharmaceutical formulations
Talebpour Z, et al.
Analytica Chimica Acta, 506(1), 97-104 (2004)
Handbook of Parkinson's Disease
Parkinson's Disease and Related Disorders, 506(4), 97-104 (2007)
L H Marcolino-Júnior et al.
Journal of pharmaceutical and biomedical analysis, 25(3-4), 393-398 (2001-05-30)
A flow injection spectrophotometric procedure was developed for determining levodopa in tablets. The determination of this drug was carried out by reacting it with lead(IV) dioxide immobilized in polyester resin packed in a solid-phase reactor and the dopachrome yielded was
Roshan Cools
Neuroscience and biobehavioral reviews, 30(1), 1-23 (2005-06-07)
It is well recognised that patients with Parkinson's disease exhibit cognitive deficits, even in the earliest disease stages. Whereas, L-DOPA therapy in early Parkinson's disease is accepted to improve the motor symptoms, the effects on cognitive performance are more complex:
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico